Yang Deok-Hwan, Kim Won Seog, Kim Seok Jin, Bae Sung Hwa, Kim Sung Hyun, Kim In Ho, Yoon Sung Soo, Mun Yeung-Chul, Shin Ho-Jin, Chae Yee Soo, Kwak Jae-Yong, Kim Hawk, Kim Min Kyoung, Kim Jin Seok, Won Jong Ho, Lee Je-Jung, Suh Cheol Won
Chonnam National University Hwasun Hospital, Jeollanam-do, Korea.
Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25. doi: 10.1016/j.bbmt.2008.11.010.
High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) offers a rescue option for T cell lymphoma patients with poor prognosis. However, the effectiveness of HDT/ASCT in patients with various peripheral T cell subtypes, optimal transplant timing, and the prognostic factors that predict better outcomes, have not been identified. We retrospectively investigated the clinical outcomes and prognostic factors for HDT/ASCT in 64 Korean patients with peripheral T cell lymphoma, unspecified (PTCL-U) between March 1995 and February 2007. The median age at transplantation was 44 years (range: 15-63 years). According to the age-adjusted International Prognostic Index (a-IPI) and the prognostic index of PTCL (PIT), 8 patients (12.5%) were in the high-risk group and 16 (26.6%) had the 2-3 PIT factors, respectively. After a median follow-up of 29.7 months, the 3-year overall survival (OS) and progression-free survival (PFS) rates were 53.0% +/- 7.5% and 44.3% +/- 7.0%, respectively. Univariate analysis showed that poor performance status, high lactate dehydrogenase (LDH) levels, high a-IPI score, high PIT classes, failure to achieve complete response (CR) at transplantation, and nonfrontline transplantation were associated with poor OS. Multivariate analysis showed that failure to achieve CR at transplantation (hazard ratio [HR] 2.23; 95% confidence interval [CI] 1.78-7.93) and 2-3 PIT factors (HR 3.76; 95% CI 1.02-5.42) were independent prognostic factors for OS. Failure to achieve CR at transplantation and high PIT are negative predictable factors for survival following HDT/ASCT in patients with PTCL-U.
大剂量化疗后自体干细胞移植(HDT/ASCT)为预后不良的T细胞淋巴瘤患者提供了一种挽救方案。然而,HDT/ASCT在不同外周T细胞亚型患者中的有效性、最佳移植时机以及预测更好结局的预后因素尚未明确。我们回顾性研究了1995年3月至2007年2月期间64例韩国未特定外周T细胞淋巴瘤(PTCL-U)患者接受HDT/ASCT的临床结局和预后因素。移植时的中位年龄为44岁(范围:15 - 63岁)。根据年龄校正的国际预后指数(a-IPI)和PTCL预后指数(PIT),分别有8例(12.5%)患者处于高危组,16例(26.6%)有2 - 3个PIT因素。中位随访29.7个月后,3年总生存率(OS)和无进展生存率(PFS)分别为53.0%±7.5%和44.3%±7.0%。单因素分析显示,体能状态差、乳酸脱氢酶(LDH)水平高、a-IPI评分高、PIT分级高、移植时未达到完全缓解(CR)以及非一线移植与不良OS相关。多因素分析显示,移植时未达到CR(风险比[HR] 2.23;95%置信区间[CI] 1.78 - 7.93)和2 - 3个PIT因素(HR 3.76;95% CI 1.02 - 5.42)是OS的独立预后因素。移植时未达到CR和高PIT是PTCL-U患者HDT/ASCT后生存的阴性预测因素。